Početna stranicaATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
Preth. zaklj. cijena
0,22 $
Godišnji raspon
0,11 $ - 0,89 $
Prosječna količina
27,54 tis.
P/E omjer
-
Prinos dividende
-
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (CAD) | pro 2023.info | Godišnja promjena |
|---|---|---|
Prihod | — | — |
Operativni troškovi | 4,60 mil. | −1,42 % |
Neto dohodak | −4,21 mil. | 2,39 % |
Neto profitabilnost | — | — |
Zarada po dionici | −0,08 | 0,50 % |
EBITDA | — | — |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (CAD) | pro 2023.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 24,91 mil. | −41,20 % |
Ukupna imovina | 56,36 mil. | −23,56 % |
Ukupne obveze | 30,42 mil. | −0,13 % |
Ukupni kapital | 25,94 mil. | — |
Dionice u optjecaju | 52,67 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,44 | — |
Povrat imovine | −19,71 % | — |
Povrat kapitala | −41,30 % | — |
Tok novca
Neto promjena novca
| (CAD) | pro 2023.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −4,21 mil. | 2,39 % |
Gotovina od poslovanja | −3,84 mil. | −6,66 % |
Gotovina iz ulaganja | 11,04 mil. | 1.975,38 % |
Gotovina iz financiranja | — | — |
Neto promjena novca | 7,20 mil. | 334,09 % |
Slobodan tok novca | −2,47 mil. | −2.419,13 % |
Više
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Osnovano
2009
Web-lokacija
Zaposlenici
11
